Evidence map›Paper›PMID 30635687›Full record

ArticleCancer immunology, immunotherapy : CII2019

Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillance.

Anna Malyshkina, Elisabeth Littwitz-Salomon, Kathrin Sutter, Jean Alexander Ross, Annette Paschen, Sonja Windmann, Simone Schimmer, Ulf Dittmer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer immunology, immunotherapy : CII, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.1field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Cytotoxic CD4Frontiers in immunology · 2023
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Anna MalyshkinaInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany. anna.malyshkina@uk-essen.de.ORCID http://orcid.org/0000-0001-5199-5472
Elisabeth Littwitz-SalomonInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.
Kathrin SutterInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.
Jean Alexander RossInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.
Annette PaschenDepartment of Dermatology, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Sonja WindmannInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.
Simone SchimmerInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.
Ulf DittmerInstitute for Virology, University Hospital Essen, University of Duisburg-Essen, Virchowstraße 179, 45147, Essen, Germany.
University of Duisburg-Essen · DEEssen University Hospital · DETrinity College Dublin · IE

Funding

Wilhelm Sander-Stiftung 2014.091.1
6 · The paper itself

Abstract

T cell responses are crucial for anti-tumor immunity. In chronic viral infections, anti-tumor T cell responses can be compromised due to various immunological mechanisms, including T cell exhaustion. To study mechanisms of anti-tumor immunity during a chronic viral infection, we made use of the well-established Friend virus (FV) mouse model. Chronically FV-infected mice are impaired in their ability to reject FBL-3 cells-a virus-induced tumor cell line of C57BL/6 origin. Here we aimed to explore therapeutic strategies to overcome the influence of T cell exhaustion during chronic viral infection, and reactivate effector CD8

Indexed as

Immunologic SurveillanceAnimalsCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell Line, TumorChronic DiseaseCytotoxicity, ImmunologicFriend murine leukemia virusMiceMice, Inbred C57BLNeoplasms, ExperimentalReceptors, OX40Retroviridae InfectionsTumor Necrosis Factor Receptor Superfamily, Member 9Receptors, OX40Tumor Necrosis Factor Receptor Superfamily, Member 9Agonistic antibodyAnti-tumor immunityCostimulatory moleculeEffector T cellsFriend retrovirus

Identifiers

PMID30635687
PMCPMC11028158
OpenAlexW2909481189

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.